ABT · News · 20261104N

Amulet 360 Product Development

ABBOTT LABORATORIES · 2026-11-04 · Importance 34 · Surprise 42

Abbott’s Amulet 360 left atrial appendage closure device achieved complete closure in 96.3% of patients with nonvalvular atrial fibrillation at one year in the pivotal VERITAS study. The study reported a 1.8% rate of ischemic stroke or systemic embolism. Amulet 360 has a CE Mark, and FDA approval is anticipated, positioning it as an alternative to standard stroke-prevention therapies.

Key facts

• At TCT 2026, Abbott announced positive one-year results from the pivotal VERITAS study for its Amulet 360 left atrial appendage closure device. source
• Amulet 360 achieved complete left atrial appendage closure in 96.3% of patients with nonvalvular atrial fibrillation at one year. source
• The Amulet 360 study reported a 1.8% rate of ischemic stroke or systemic embolism. source
• FDA approval for Amulet 360 is anticipated. source
• Abbott is awaiting FDA approval for Amulet 360 in the U.S.; the device is already CE marked in Europe. source
• Amulet 360 has a CE Mark. source